Login to Your Account



Psioxus enters clinic with tumor-targeting gene therapy, earns milestone from BMS

By Nuala Moran
Staff Writer

Tuesday, December 12, 2017

LONDON – Psioxus Therapeutics Ltd. has received approval for a phase I trial of NG-348, the first of its gene therapy for tumor products, triggering a $15 million milestone from partner Bristol-Myers Squibb Co. (BMS).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription